uniQure (QURE) AI Stock Analysis

• Market Cap: $758.81M
• Dividend Yield: N/A
• Average Volume (3M): 1.27M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.56
• Revenue Growth: 6.30%
• EPS Growth: 29.17%
• Country: US
• Employees: 209
• Sector: Healthcare
• Sector Strength: 42
• Industry: Biotechnology
• EPS (TTM): -0.82
• Shares Outstanding: 54,748,497
• 10 Day Avg. Volume: 1,383,276
• 30 Day Avg. Volume: 1,265,746
• PEG Ratio: -0.61
• Price to Book (P/B): 8.87
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -27.21
• Enterprise Value/Market Cap: 3.38
• Enterprise Value/Revenue: 24.72
• Enterprise Value/Gross Profit: 311.14
• Enterprise Value/Ebitda: -3.78
• 1Y Price Target: $40.00
• Price Target Upside: 188.60% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 8

• Rating: 54 Neutral
• Price Target: $15.50 ▲(11.83%Upside)

uniQure's financial performance, characterized by significant losses and cash flow challenges, heavily impacts its overall score. However, strong regulatory progress, particularly with AMT-130, and a solid cash position provide potential for future growth. Technical indicators and recent corporate events offer moderate support, but valuation remains a concern.

Positive Factors

Clinical Data

High-dose AMT-130 showed an 80% reduction of disease progression based on cUHDRS versus external control datasets.

Regulatory Approval

Reaching alignment with the FDA is seen as a very important de-risking event for QURE and further clarity on the content and timing of the BLA submission should bring investors some comfort.

Regulatory Strategy

The FDA reaffirmed its support of an accelerated approval path for AMT-130, a gene therapy for Huntington’s disease.

Negative Factors

Data Analysis Concerns

The key question going forward is what the hurdle for clinical success is in the SAP.

Investor Concerns

Some investors might see the change here as a red flag, it's also very possible that QURE proposed the use of ENROLL-HD because they think it gives them the best shot.

uniQure Business Overview & Revenue Model

Company Description

uniQure N.V. is a biotechnology company engaged in the research, development, and commercialization of gene therapies. Headquartered in the Netherlands, the company focuses primarily on the treatment of rare and genetic diseases. Its core products leverage its proprietary gene therapy platform, based on adeno-associated virus (AAV) vectors, to deliver therapeutic genes to patients. uniQure's lead product candidates target conditions such as hemophilia B, Huntington's disease, and cardiovascular disorders.

How the Company Makes Money

uniQure generates revenue through the development and commercialization of its gene therapy products. The company's primary revenue streams include milestone payments and royalties from licensing agreements with pharmaceutical partners. uniQure collaborates with these partners to co-develop and co-commercialize its therapies, receiving milestone payments upon achieving specific development or regulatory milestones. Additionally, the company earns royalties on the sales of commercialized products. Significant partnerships, such as those with CSL Behring for the hemophilia B program, contribute to its earnings by providing funding and resources for product development and market access. uniQure also benefits financially from government grants and research collaborations, which support its research and development activities.

uniQure Financial Statement Overview

Summary

uniQure faces significant financial hurdles characterized by fluctuating revenue, consistent net losses, and high leverage. Negative profitability metrics and cash flow challenges indicate a need for strategic adjustments to achieve sustainable growth.

Income Statement

uniQure has demonstrated significant volatility in revenue and profitability over recent years. The TTM (Trailing-Twelve-Months) shows a gross profit margin of 40.76%, but a net profit margin of -1077.18%, indicating substantial losses relative to revenue. The revenue growth has been erratic, with periods of significant decline, such as the 81.12% drop from 2021 to 2022. The negative EBIT and EBITDA margins underscore ongoing operational challenges.

Balance Sheet

The balance sheet reflects high leverage, with a debt-to-equity ratio of 1.97 in the TTM, indicating significant reliance on debt financing. The equity ratio is 5.57%, suggesting a low proportion of assets financed by equity. While cash reserves are strong, the negative stockholders' equity in 2024 raises concerns about financial stability.

Cash Flow

Cash flow analysis reveals negative operating and free cash flows, highlighting ongoing cash burn challenges. The TTM indicates a free cash flow to net income ratio of 0.77, suggesting inefficiencies in converting revenue to cash flow. The operating cash flow to net income ratio of 0.76 further underscores cash flow management issues.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	20.20M	27.12M	15.84M	106.48M	524.00M	37.51M
Gross Profit	8.23M	8.79M	2.21M	103.14M	499.03M	-84.89M
EBITDA	-153.84M	-160.75M	-253.10M	-108.02M	319.00M	-126.97M
Net Income	-217.57M	-239.56M	-308.48M	-126.79M	329.59M	-125.02M
Balance Sheet
Total Assets	605.40M	556.54M	831.69M	704.96M	809.18M	340.39M
Cash, Cash Equivalents and Short-Term Investments	409.01M	367.52M	617.89M	352.84M	556.26M	244.93M
Total Debt	66.20M	66.06M	138.41M	142.89M	135.72M	71.54M
Total Liabilities	571.72M	563.29M	624.02M	228.96M	213.40M	96.49M
Stockholders Equity	33.69M	-6.75M	207.67M	476.01M	595.78M	243.91M
Cash Flow
Free Cash Flow	-167.42M	-186.10M	-153.08M	-162.75M	270.52M	-144.31M
Operating Cash Flow	-166.25M	-182.73M	-145.93M	-145.06M	287.96M	-134.83M
Investing Cash Flow	121.06M	162.97M	-205.69M	-182.73M	-67.39M	-9.48M
Financing Cash Flow	21.18M	-59.49M	362.72M	1.45M	94.86M	7.44M

uniQure Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 13.86
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For QURE, the sentiment is Neutral. The current price of 13.86 is below the 20-day moving average (MA) of 15.18, below the 50-day MA of 14.36, and above the 200-day MA of 11.47, indicating a neutral trend. The MACD of -0.09 indicates Positive momentum. The RSI at 42.61 is Neutral, neither overbought nor oversold. The STOCH value of 22.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for QURE.

uniQure Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CVAC	76 Outperform	$1.21B	5.93	34.46%	―	799.36%	―
QURE	54 Neutral	$758.81M	―	-241.16%	―	6.30%	29.17%
Sector *	51 Neutral	$7.41B	0.36	-61.88%	2.33%	17.09%	1.64%
DAWN	50 Neutral	$655.82M	―	-17.80%	―	―	56.10%
NTLA	50 Neutral	$990.26M	―	-57.92%	―	-13.37%	2.57%
SYRE	43 Neutral	$918.58M	2.31	-50.47%	―	-100.00%	94.68%
RCKT	40 Underperform	$272.58M	―	-60.45%	―	―	6.99%

uniQure Corporate Events

uniQure Shareholders Approve Key Proposals at Annual Meeting

On June 11, 2025, uniQure held its Annual Meeting where shareholders voted on several key proposals. The meeting resulted in the re-election of Matthew Kapusta as executive director and Dr. Robert Gut and Dr. Jeremy Springhorn as non-executive directors, each to serve until the 2028 annual general meeting. Additionally, all other proposals, including the adoption of the 2024 Dutch statutory annual accounts, discharge of board members’ liabilities, and various authorizations related to shares and compensation, were approved.

The most recent analyst rating on (QURE) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on uniQure stock, see the QURE Stock Forecast page.

uniQure Aligns with FDA for AMT-130 BLA Approval

On June 2, 2025, uniQure announced alignment with the FDA on key components necessary for a Biologics License Application (BLA) for AMT-130, a gene therapy for Huntington’s disease. This alignment supports an accelerated approval pathway, with a BLA submission planned for early 2026. The company is leveraging extensive clinical data and FDA guidance to pursue the first disease-modifying treatment for Huntington’s disease, reflecting a significant step forward in addressing this unmet medical need.

The most recent analyst rating on (QURE) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on uniQure stock, see the QURE Stock Forecast page.

uniQure Amends CEO Employment Agreement

On April 15, 2025, uniQure, Inc., a subsidiary of uniQure N.V., entered into an Amended and Restated Employment Agreement with its CEO, Matthew Kapusta. The agreement outlines Mr. Kapusta’s compensation, including a base salary of $676,700, potential bonuses, and long-term incentives, as well as severance benefits in case of termination without cause or for good reason. These benefits vary depending on whether the termination occurs around a change in control of the company, with provisions for salary continuation, bonus payments, and accelerated vesting of equity awards.